Amicus Therapeutics Inc (FOLD)

Currency in USD
6.790
-0.140(-2.02%)
Closed·
After Hours
6.700-0.090(-1.33%)
·
FOLD Scorecard
Full Analysis
Net income is expected to grow this year
FOLD is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
6.5956.950
52 wk Range
5.51012.650
Key Statistics
Prev. Close
6.79
Open
6.94
Day's Range
6.595-6.95
52 wk Range
5.51-12.65
Volume
4.08M
Average Volume (3m)
4.95M
1-Year Change
-32.1%
Book Value / Share
0.66
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
FOLD Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
16.091
Upside
+136.98%
Members' Sentiments
Bearish
Bullish
ProTips
3 analysts have revised their earnings upwards for the upcoming period

Amicus Therapeutics Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Neutral
Technical Indicators
Strong Sell
Moving Averages
Strong Buy

Amicus Therapeutics Inc Company Profile

Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering novel medicines for rare diseases in the United States and internationally. The company’s commercial product and product candidates consist of Galafold, an orally administered monotherapy for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, a novel two-component treatment program for adults living with late-onset Pompe disease. It has collaboration and license agreement with GlaxoSmithKline to develop and commercialize Galafold. Amicus Therapeutics, Inc. was incorporated in 2002 and is headquartered in Princeton, New Jersey.

Amicus Therapeutics Inc Earnings Call Summary for Q2/2025

  • Amicus Therapeutics reported Q2 2025 revenue of $154.7M, up 22% YoY, beating estimates. EPS of $0.01 surpassed forecasted loss of $0.11.
  • Pompe therapy revenue grew 58% at constant exchange rates. Company achieved positive non-GAAP net income of $1.9M.
  • Full-year revenue guidance reaffirmed at 15-22% growth. GAAP profitability expected in H2 2025.
  • Stock rose 2.77% pre-market. Analysts see upside potential with price targets ranging from $9 to $22.
  • Management confident in growth trajectory, citing untapped potential for Galafold and expansion into new markets like Australia and Canada.
Last Updated: 31/07/2025, 16:12
Read Full Transcript

Compare FOLD to Peers and Sector

Metrics to compare
FOLD
Peers
Sector
Relationship
P/E Ratio
−54.9x−1.1x−0.5x
PEG Ratio
−0.82−0.060.00
Price/Book
10.2x2.2x2.6x
Price / LTM Sales
3.7x9.2x3.3x
Upside (Analyst Target)
130.9%308.0%43.4%
Fair Value Upside
Unlock18.5%7.1%Unlock

Analyst Ratings

10 Buy
2 Hold
0 Sell
Ratings:
12 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 16.091
(+136.98% Upside)

Earnings

Latest Release
Jul 31, 2025
EPS / Forecast
0.01 / -0.11
Revenue / Forecast
154.70M / 146.73M
EPS Revisions
Last 90 days

FOLD Income Statement

People Also Watch

259.61
AVAV
-1.33%
17.96
SRPT
+10.46%
2.240
UAVS
-3.03%
5.140
ARDX
-1.15%
19.580
ZETA
-3.21%

FAQ

What Stock Exchange Does Amicus Trade On?

Amicus is listed and trades on the Nasdaq Stock Exchange stock exchange.

What Is the Stock Symbol for Amicus?

The stock symbol for Amicus is "FOLD."

What Is the Amicus Market Cap?

As of today, Amicus market cap is 2.09B.

What Is Amicus's Earnings Per Share (TTM)?

The Amicus EPS (TTM) is -0.12.

When Is the Next Amicus Earnings Date?

Amicus will release its next earnings report on 04 Nov 2025.

From a Technical Analysis Perspective, Is FOLD a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.

How Many Times Has Amicus Stock Split?

Amicus has split 0 times.

How Many Employees Does Amicus Have?

Amicus has 499 employees.

What is the current trading status of Amicus (FOLD)?

As of 08 Aug 2025, Amicus (FOLD) is trading at a price of 6.79, with a previous close of 6.79. The stock has fluctuated within a day range of 6.60 to 6.95, while its 52-week range spans from 5.51 to 12.65.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.